HomeBusinessEnergy Sector, Oil, & Gas Stock NewsSpyre (SYRE) CEO On IBD Market Growth

Spyre (SYRE) CEO On IBD Market Growth

Spyre (SYRE) is a biotech company that aims to create the next-generation of inflammatory bowel disease products. CEO Cameron Tuttle joins Oliver Renick to discuss the company as it began trading on the NASDAQ following an acquisition of Aeglea. Tuttle talks about how the IBD market is expected to grow to $29B by 2028, as the CDC estimates that 3.1M Americans have been diagnosed with IBD. Tune in to find out more about the stock market today.

Morning Trade Live

06 Dec 2023

SHARE

ON AIR
4:30 am
Next Gen Investing
replay
12:00 am
Fast Market
REPLAY
1:00 am
Trading 360
REPLAY
2:00 am
Next Gen Investing
REPLAY
education
3:00 am
Your First Trade
REPLAY
3:30 am
Trading 360
REPLAY
ON AIR
4:30 am
Next Gen Investing
REPLAY
education
5:30 am
Your First Trade
REPLAY
6:00 am
Fast Market
REPLAY
7:00 am
Futures
8:00 am
Morning Trade Live
10:00 am
Trading 360
11:00 am
Fast Market
12:00 pm
Next Gen Investing
1:00 pm
The Watch List
2:00 pm
Market On Close
3:30 pm
Market Overtime
REPLAY
4:00 pm
Trading 360
REPLAY
5:00 pm
Fast Market
REPLAY
6:00 pm
Next Gen Investing
REPLAY
7:00 pm
Market Overtime
REPLAY
education
7:30 pm
Your First Trade
REPLAY
8:00 pm
Trading 360
REPLAY
9:00 pm
Market Overtime
REPLAY
education
9:30 pm
Your First Trade
REPLAY
10:00 pm
Fast Market
REPLAY
11:00 pm
Trading 360
REPLAY

Get the Market Minute

Daily insights for every investor

coming soon

We are now

coming soon

We are now